The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

NCT07134205 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: JMT101
DRUG: Irinotecan
DRUG: Regorafenib

Sponsor

Shanghai JMT-Bio Inc.